Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug DevelopmentPRNewsWire • 06/08/26
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig ProgramSeeking Alpha • 05/19/26
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 AdvancementSeeking Alpha • 03/02/26
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026PRNewsWire • 02/17/26
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of DirectorsPRNewsWire • 02/12/26
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 MillionPRNewsWire • 12/17/25
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025PRNewsWire • 10/13/25